With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
April 21, 2010
With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
Although Qiagen is prioritizing Rx/Dx partnerships with pharma, that doesn't mean it won't look into bringing tests to market with payors or on its own.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Medco Around for Dx Shops Developing PGx Tests Independently, Who Needs Pharma?
April 14, 2010 / Pharmacogenomics Reporter - FDA Update to Erbitux, Vectibix Labels Encourages Rx/Dx Co-development, Industry Expert Says
July 22, 2009 / Pharmacogenomics Reporter - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - Amgen Lays Out Timeline for KRAS Mutation Studies to Dispel Perceptions of Unethical Rx Development
February 24, 2010 / Pharmacogenomics Reporter